ClinicalTrials.gg
RecruitingNCT06154343Updated Dec 4, 2023

A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

A Phase 1 interventional study of GQ1005 in HER2 Expressing or Mutated Advanced Malignant Solid Tumors, sponsored by GeneQuantum Healthcare (Suzhou) Co., Ltd.. Recruiting at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-04.

Sponsored by GeneQuantum Healthcare (Suzhou) Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Nov 2022, registered Nov 2023).
  • Started Nov 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1005 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.

02

Conditions studied

  • HER2 Expressing or Mutated Advanced Malignant Solid Tumors
03

In context

Lead sponsor

GeneQuantum Healthcare (Suzhou) Co., Ltd. is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

The general inclusion criteria for dose escalation in Part 1 and dose expansion in Part 2 are as follows:

  1. Voluntary agreement to provide written ;
  2. Aged 18 years or older, both male and female.
  3. The expected survival time is more than 3 months.
  4. performance status Score 0 or 1.
  5. ≥ 50% by ECHO or MUGA scan within 28 days prior to the first dose of study drug.
  6. or cytologically confirmed with at least 1 as assessed by v1.1.
  7. Good organ function, confirmed by the following laboratory test results at Screening and within 7 days prior to the first dose of study drug:

    count ≥ 100,000/mm3; ≥ 9g/dL; ≥ 1500/mm3; Serum CREA ≤ 1.5 × , or estimated CREA clearance ≥ 60 mL/min ( equation); and AST ≤ 3 × ULN (≤ 5 x ULN if liver are present); Total ≤ 1.5 x ULN for subjects with Gilbert's syndrome or ≤ 2 x ULN for subjects with liver metastases at baseline; and activated partial thromboplastin time ≤ 1.5 × ULN;

  8. Adequate prior to the first treatment, defined as follows:

    Major surgery ≥ 4 weeks; radiotherapy ≥ 4 weeks (≥ 2 weeks if the radiotherapy is palliative stereotactic radiotherapy without abdominal involvement); seed-radioactive therapy ≥ 3 months; Nuclein therapy ≥ 3 months; autotransplantation ≥ 3 months; Hormone therapy ≥ 2 weeks or as per investigator's judgment (breast cancer subjects) Chemotherapy or targeted therapy (including antibody drug therapy) ≥ 2 weeks (5-FU-based drugs, folinic acid preparations and/or weekly paclitaxel therapy);

    • 2 weeks (or 5 half-lives, whichever is longer) (tyrosine kinase inhibitor);
    • 4 weeks (-targeted biological therapy);
    • 6 weeks (nitrosourea or mitomycin C);
    • 3 weeks (any other chemotherapy/targeted therapy);
    • 2 weeks (Chinese patent medicine with clear antitumor indication) antitumor immunotherapy ≥ 4 weeks; Any drug or treatment ≥ 4 weeks; Strong inhibitors of cytochrome P450 enzyme 3A4 () ≥ 1 week; Organic Anion Transport Polypeptide (OATP) Inhibitors ≥ 1 week;

    Inclusion criteria for the dose escalation phase of Part 1 only:

  9. Failure of standard treatment, or intolerance, or absence of standard treatment, confirmed by pathology, HER2 expression (including IHC1+, IHC2+, IHC3+ and/or ISH*+) or subjects with advanced/unresectable or metastatic solid tumors with HER2 exon 19 or 20 mutations (non-small cell lung cancer only). If only ISH*, NGS reports are available, contact the Medical Monitor.

    Inclusion criteria for part 2a only:

  10. Failure of standard treatment, intolerance, or absence of standard treatment, confirmed by pathology, HER2 overexpression (IHC 3+ or IHC 2+ and ISH* +) Advanced/unresectable or metastatic breast cancer.

    Inclusion criteria for part 2b only:

  11. Advanced breast cancer with low HER2 expression, unresectable, or metastatic breast cancer that has failed standard treatment, or is not tolerated, or has no standard treatment, is confirmed by pathology. (IHC 2+ and ISH*- or ISH unknown, or IHC 1+).

    Inclusion criteria for part 2c only:

  12. Non-small cell lung cancer with a HER2 exon 19 or 20 mutation that has failed, or is not tolerated, or is confirmed by a documented pathology without standard treatment.

    Inclusion criteria for part 2d only:

  13. Advanced/unresectable or metastatic solid tumors with HER2 expression that have failed standard therapy, are not tolerated, or are without standard therapy, and are confirmed by pathology, with HER2 overexpression preferred. (IHC 3+ or IHC 2+ or ISH* +) Adenocarcinoma of gastric and gastroesophageal junction; Other preferred tumor types include HER2 overexpression. (IHC 3+ or IHC 2+ or ISH* +) Urothelial cancer, biliary tract cancer, endometrial cancer; Breast cancer and non-small cell lung cancer are excluded.

    • ISH+: FISH or two-color in situ hybridization (DISH).

Exclusion Criteria:

Subjects must not meet any of the following exclusion criteria to be enrolled in the study.

  1. Clinically active , defined as untreated and symptomatic, or requiring treatment with or anticonvulsants to control associated symptoms. Subjects with treated asymptomatic brain metastases who do not require steroid therapy may be included in the study if they have recovered from the acute toxicity of radiation therapy.
  2. Cardiovascular dysfunction or cardiac conditions, including but not limited to:

    • Symptomatic CHF ( classes II to IV) or severe cardiac arrhythmia requiring treatment
    • History of myocardial infarction or troponin levels consistent with myocardial infarction (defined by the American College of Cardiology guidelines) within 6 months prior to the first dose, and unstable angina pectoris within 6 months prior to the first dose of study drug;
    • prolongation at Screening >460 milliseconds (ms) (male) and >470 ms (female) except for right bundle branch block.
  3. Clinically significant acute and chronic lung disease. (e.g., interstitial pneumonia, pulmonary infection, pulmonary fibrosis, and severe radiation pneumonitis), or subjects with suspected pulmonary disease based on imaging at screening, or subjects requiring oxygen.
  4. People with known to recombinant humanized anti-HER2 monoclonal antibody-DXd conjugate drugs and their components or to humanized monoclonal antibody products.
  5. Poorly controlled pleural, ascites, or pericardial effusions.
  6. Toxicity that has not resolved from prior antineoplastic therapy, defined as toxicity (other than alopecia) that has not resolved to ≤ Grade 1 or baseline levels, is at the discretion of the investigator for the eligibility of subjects with chronic Grade 2 toxicities.
  7. The prior anthracycline exposure dose met the following criteria: adriamycin > 500mg/m2; Epirubicin >900mg/m2; Pirarubicin > 950mg/m2; Mitoxanthraquinone >120mg/m2; other (i.e. liposomal doxorubicin or other anthracycline >equivalent to 500 mg/m2 of doxorubicin); If more than one anthracycline is used, the cumulative dose must not exceed the equivalent of 500 mg/m2 of doxorubicin.
  8. There is an active infection requiring treatment with intravenous antibiotics, antivirals, or antifungals.
  9. Known infection.
  10. Active virus infection. (HCV antibody positive and HCV-RNA higher than the upper limit of reference value); Active virus infection. (HBsAg positive and/or HBcAb positive and HBV-DNA quantitation ≥2000 IU/ml);, to be eligible for enrollment, subjects with chronic hepatitis B will have to agree to monthly DNA testing and receive appropriate antiviral therapy as indicated.
  11. was administered within 30 days prior to the first dose of study drug.
  12. Previous or current evidence of any concomitant disease, treatment, or laboratory abnormality that the investigator believes may confound the results of the trial or interfere with subject participation and compliance.
  13. He has received treatment with an antibody-conjugated drug comprising a topoisomerase I inhibitor ezotecan derivative.
  14. Breastfeeding women or women with confirmed pregnancy by a pregnancy test within 7 days prior to the first treatment.
  15. Reluctant to during the study and for at least 7 months after the last dose of study drug.
  16. Subjects with multiple primary malignancies within the past 3 years, with the exception of fully resected non-melanoma skin cancer, cured disease in situ, cured contralateral breast cancer.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    GQ1005 will be administered intravenously every 21 days. Dose Escalation will be guided by Bayesian Optimal Interval (BOIN) Design. Multiple dose grouping

    Drug: GQ1005

  • Experimental
    Dose Expansion

    GQ1005 at the recommended phase II dose (RP2D) will be administered intravenously every 21 days. Dose expansion will further evaluate the MTD or RP2D in different types of malignant solid tumor in four cohorts.

    Drug: GQ1005

Interventions

  • DrugGQ1005

    an antibody drug conjugate

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events (AEs)

    Incidence and severity of Treatment-emergent adverse events, treatment-related adverse events and serious adverse events, according to NCI-CTCAE Version 5.0 (The number of participants who had treatment-related side effects in population who had received one therapy at least).

    Time frame: Up to 2 years

  2. Dose Limiting Toxicities (DLTs)

    Adverse events will be assessed using NCI CTCAE version 5.0 and will be evaluated by the investigator and the sponsor for the eligibility of DLT.

    Time frame: From first dose to the end of Cycle 1, 21 days

  3. Maximal Tolerance Dose (MTD) or recommended phase II dose (RP2D)

    The SRC will also determine the MTD/RP2D based on the totality of data for all tested dose levels.

    Time frame: After each cohort completes the DLT observation period (Day 1 to Day 21 after the first dose of study treatment) or has a DLT or becomes not DLT-evaluable

Secondary outcomes

  1. Maximum concentration (Cmax) of GQ1005

    The pharmacokinetics(PK) profile of GQ1005

    Time frame: Up to2 years

  2. Time of peak plasma concentration (Tmax)

    The pharmacokinetics(PK) profile of GQ1005

    Time frame: Up to2 years

  3. Area under the plasma concentration time curve (AUC) of GQ1005

    The pharmacokinetics(PK) profile of GQ1005

    Time frame: Up to 2 years

  4. Overall response rate (ORR)

    The objective response rate will be analyzed according to the RECIST 1.1 standard tumor evaluation

    Time frame: Up to 2 years

  5. Duration of Response (DoR)

    DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death

    Time frame: Up to 2 years

  6. Disease control rate (DCR)

    DCR is defined as the rate of the sum of CR, PR and SD according to the RECIST 1.1 standard tumor evaluation.

    Time frame: Up to 2 years

  7. Time-to-response (TTR)

    To preliminarily evaluate TTR in patients with advanced solid tumors

    Time frame: Up to 2 years

  8. Progression-free survival (PFS)

    Progression free survival (PFS) refers to the time from the date of first administration to the first researcher's evaluation of disease progression or death (calculated by the event that occurred first). The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard

    Time frame: Up to 2 years

  9. Overall Survival (OS)

    Overall survival (OS) refers to the time from the date of first administration to (for any reason) death. The disease progression will be evaluated by the researchers according to the RECIST 1.1 standard

    Time frame: Up to 2 years

  10. Immunogenicity (anti-drug antibody ADA)

    Percentage of subjects producing detectable anti-drug antibodies (ADA)

    Time frame: Up to 2 years

07

Study locations

20 of 20 sites recruiting
  • Chinese PLA general hospital
    Beijing, Beijing 100039, China
    Recruiting
    • Bo Yang, MD. Ph.D · Principal investigator
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400042, China
    Recruiting
    • The FAHOZ University · Contact
    • Qiao Cheng, MD.Ph.D · Principal investigator
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Recruiting
    • Wu Zhuang, MD. Ph.D · Principal investigator
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Recruiting
    • Rongbo Lin, MD.Ph.D · Principal investigator
  • The First Affiliated Hospital of Haerbin Medical University
    Haerbin, Heilongjiang 150007, China
    Recruiting
    • Zhiwei Li, MD.Ph.D · Principal investigator
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan 453199, China
    Recruiting
    • Yinghua Ji, MD.Ph.D · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
    Recruiting
    • Qiming Wang, MD. Ph.D · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Recruiting
    • Xingya Li, MD. Ph.D · Principal investigator
  • Affiliated Drum Tower Hospital, Medical School of Nanjing University
    Nanjing, Jiangsu 210008, China
    Recruiting
    • Jia Wei, MD. Ph.D · Principal investigator
  • Shengjing hospital of China medical universty
    Shenyang, Liaoning 110136, China
    Recruiting
    • Caigang Liu, MD. Ph.D · Principal investigator
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Recruiting
    • Linlin Wang, MD.Ph.D · Principal investigator
    • Yuping Sun, MD.Ph.D · Principal investigator
  • Linyi Cancer Hospital
    Linyi, Shandong 276002, China
    Recruiting
    • Jingfen Wang, MD. Ph.D · Principal investigator
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264099, China
    Recruiting
    • Jian Chen, MD.Ph.D · Principal investigator
  • Fudan university Shanghai Cancer Center
    Shanghai, Shanghai 200032, China
    Recruiting
    • Biyun wang, MD. Ph.D · Principal investigator
    • Jian zhang, MD. Ph.D · Principal investigator
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai, China
    Recruiting
    • Caicun Zhou, MD. Ph.D · Principal investigator
  • The First Affiliated Hospital of Xi'an University
    Xi'an, Shangxi 710061, China
    Recruiting
    • Enxiao Li, MD.Ph.D · Principal investigator
  • Sichuan Cancer Hospital
    Chengdu, Sichuang 610042, China
    Recruiting
    • Jin Lu, MD.Ph.D · Principal investigator
  • Suining Central Hospital
    Suining, Sichuan 629099, China
    Recruiting
    • Hongwei Yang, MD. Ph.D · Principal investigator
  • Tianjin medical university cancer institute & hospital
    Tianjin, Tianjin 300181, China
    Recruiting
    • Ting Deng, MD. Ph.D · Principal investigator
  • Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310020, China
    Recruiting
    • Xian Wang, MD. Ph.D · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Dec 2024, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2023
First posted
Dec 4, 2023
StartActual
Nov 23, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jul 30, 2025
Last update
Dec 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06154343
Lead sponsor
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Dec 4, 2023
Start date
Nov 23, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Jul 30, 2025 (estimated)
Last update
Dec 4, 2023

Study contacts

Yan Shi
Contact
shiy@genequantum.com
0512-66526166

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion